Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan.
Am J Kidney Dis. 2010 Oct;56(4):720-7. doi: 10.1053/j.ajkd.2010.06.015.
Fetuin A, a predictor of mortality in dialysis patients, is associated with vascular calcification and atherosclerosis in hemodialysis (HD) patients. Whether it predicts arteriovenous (AV) access patency is unknown. This study aimed to investigate the association between fetuin A and AV access patency in HD patients.
Prospective observational study.
SETTING & PARTICIPANTS: 238 prevalent HD patients (127 women and 111 men; mean age, 60 ± 12 years) were followed up for AV access patency for 32 months.
Tertiles of baseline circulating fetuin A levels, corresponding to 0.15-0.25, 0.26-0.32, and 0.33-0.51 g/L.
The major outcome was loss of unassisted AV access patency, defined as AV access thrombosis or need for intervention.
Fetuin A and other markers of inflammation.
100 patients had loss of AV access patency (42%) on follow-up. Patients in the lowest fetuin A tertile had the worst AV access patency (log-rank test, χ(2) = 8.68; P = 0.01). Using Cox proportional hazards regression with patients in the lowest fetuin A tertile as reference, patients in the intermediate tertile had an HR of 0.49 (95% CI, 0.29-0.82), whereas those in the highest fetuin A tertile had an HR of 0.43 (95% CI, 0.25-0.75) for loss of AV access patency. Similarly, considering patients using AV fistulas or grafts separately, patients in the highest fetuin A tertile had less risk of losing AV access patency than patients in the other tertiles (HR, 0.40 [95% CI, 0.19-0.84] for patients with AV fistulas and HR, 0.25 [95% CI, 0.10-0.65] for patients with AV grafts).
Focus on the patency of prevalent rather than new AV access in maintenance hemodialysis patients.
Fetuin A deficiency is associated with a higher risk of loss of AV access patency in either native AV fistulas or AV grafts in HD patients.
胎球蛋白 A 是透析患者死亡率的预测因子,与血液透析(HD)患者的血管钙化和动脉粥样硬化有关。它是否可以预测动静脉(AV)通路通畅性尚不清楚。本研究旨在探讨 HD 患者胎球蛋白 A 与 AV 通路通畅性之间的关系。
前瞻性观察性研究。
238 例现患 HD 患者(127 名女性和 111 名男性;平均年龄 60±12 岁)随访 32 个月以观察 AV 通路通畅性。
基线循环胎球蛋白 A 水平的三分位,对应于 0.15-0.25、0.26-0.32 和 0.33-0.51 g/L。
未辅助 AV 通路通畅性丧失,定义为 AV 通路血栓形成或需要干预。
胎球蛋白 A 和其他炎症标志物。
100 例患者在随访中出现 AV 通路通畅性丧失(42%)。胎球蛋白 A 最低三分位组的患者 AV 通路通畅性最差(对数秩检验,χ²=8.68;P=0.01)。使用 Cox 比例风险回归,以胎球蛋白 A 最低三分位组为参考,胎球蛋白 A 中等三分位组的 HR 为 0.49(95%CI,0.29-0.82),而胎球蛋白 A 最高三分位组的 HR 为 0.43(95%CI,0.25-0.75)。同样,考虑到分别使用 AV 瘘或移植物的患者,胎球蛋白 A 最高三分位组的患者比其他三分位组的患者更不易发生 AV 通路通畅性丧失(HR,0.40[95%CI,0.19-0.84],用于 AV 瘘患者;HR,0.25[95%CI,0.10-0.65],用于 AV 移植物患者)。
关注维持性血液透析患者中现患而非新的 AV 通路通畅性。
胎球蛋白 A 缺乏与 HD 患者的天然 AV 瘘或 AV 移植物的 AV 通路通畅性丧失风险增加有关。